Stay updated on GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Sign up to get notified when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.

Latest updates to the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version v2.15.0 to v2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include new details about the study design for GS030, specifically the addition of dose-escalation cohorts and a revision number change. However, significant content regarding the study's objectives and selection criteria has been removed.SummaryDifference19%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GS030 Dose-escalation Safety in Retinitis Pigmentosa Clinical Trial page.